ESR2 and neoplasm: Tumor mutation burden analysis indicated that in 433 STAD samples, 73 samples showed altered mutation frequencies in PRG signatures, with mutation rates of 4% for COL8A1, 3% for DDB1, 3% for PARP1, and 3% for ESR2 (Fig 1C).